Introduction
Secondary cytopenia is a common complication after hematopoietic cell transplantation (HCT).
Causes include viral infection, septicemia, graft-versus-host disease (GVHD), and myelotoxic drugs. [1] [2] [3] [4] [5] Of the commonly used drugs with myelotoxic potential, ganciclovir is particularly prone to cause neutropenia, which occurs in up to 40% of allograft recipients and may increase the risk of invasive bacterial and fungal infections. 1, 6 The underlying mechanism of ganciclovirrelated neutropenia is a dose-dependent inhibition of DNA-polymerase in hematopoietic progenitor cells. 7 We previously reported that ganciclovir-related neutropenia is associated with low marrow cellularity, hyperbilirubinemia, and elevated serum creatinine levels after myeloablative conditioning (M-HCT). 1 However, it is not known how nonmyeloablative conditioning (NM-HCT) influences the incidences of secondary cytopenias in general and ganciclovir-related neutropenia in particular.
Less toxic nonmyeloablative conditioning regimens that can be successfully applied to elderly patients and/or patients with comorbidities have been developed. [8] [9] [10] [11] [12] [13] Nonmyeloablative conditioning does not eradicate host hematopoiesis and allows relatively prompt hematopoietic recovery within 28 days after transplantation. 14,15 Therefore, NM-HCT may be associated with a lower incidence of cytopenias, including ganciclovir-related neutropenia. In addition, the increased use of hematopoietic growth factors for secondary neutropenia at moderate levels in recent years may also be associated with a lower risk of profound levels of neutropenia.
The purpose of this study was to examine risk factors for the occurrence of cytopenias 28 days after HCT as a surrogate for secondary neutropenia overall, and ganciclovir-related neutropenia in particular.
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Design and Methods

Study population
This retrospective study population consisted of 2162 consecutive patients who underwent HCT from 1998 to 2006 at the Fred Hutchinson Cancer Research Center (FHCRC) (Seattle, WA).
The retrospective analysis was approved by the Institutional Review Board of the FHCRC.
Informed consent was obtained from all the patients before HCT. We compared events between 534 patients undergoing NM-HCT and 1628 contemporaneous patients undergoing M-HCT who served as a comparison group (Table 1) . Clinical and laboratory data were extracted from the computerized database and from patient charts.
The most common regimens for NM-HCT were fludarabine (30 mg/m 2 /day for 3 consecutive days) and low-dose TBI (2 Gy, day 0), or low-dose TBI (2 Gy, day 0) alone. In contrast, many different types of conditioning regimens were used for M-HCT. The most common regimen for M-HCT consisted of cyclophosphamide (60 mg/kg/day for 2 consecutive days) followed by TBI (12 Gy or 13.2 Gy) or busulfan (4 mg/kg/day for 4 consecutive days)
followed by cyclophosphamide (60 mg/kg/day for 2 consecutive days). The NM-HCT group included more elderly patients, almost exclusive use of peripheral blood stem cells as a stem cell source, and higher doses of transplanted CD34+cells than those in the M-HCT group (Table   1 ).
In terms of GVHD prophylaxis, M-HCT patients most commonly received a combination of a calcineurin inhibitor [either cyclosporine (CSP) or tacrolimus] and short-term methotrexate (15 mg/m 2 intravenously on day 1, and 10 mg/m 2 on day 3, 6, and 11). All NM-HCT patients received post-grafting immune suppressants including mycophenolate mofetil (MMF) and a calcineurin inhibitor, CSP or tacrolimus (Table 1) MMF was administrated 15 mg/kg orally twice a day from day 0 to day 27 and discontinued for the human leukocyte antigen (HLA) matched-related NM-HCT patients; while for the unrelated NM-HCT patients MMF was given at a dose of 15 mg/kg orally 2 or 3 times a day from day 0 to day 40, with a taper to day 96. For the single HLA-antigen and combined HLA-antigen and allele mismatched NM-HCT patients, 15 mg/kg MMF was given 3 times a day and then tapered at day 100 over 2 months.
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Transfusion requirements
Red blood cell transfusions. Red blood cells were routinely transfused when the hematocrit fell below 26%. In patients with severe uremia, other causes of platelet dysfunction, active bleeding, or thrombocytopenic refractory to platelet transfusion, the hematocrit was maintained at ≥ 30%. A hematocrit of ≥ 30% was also maintained in patients with a history of cardiac or peripheral vascular disease, or in patients > 65 years of age.
Platelet transfusions.
A platelet threshold for transfusion of 1.0 × 10 10 /L was used for clinically stable, afebrile patients without evidence of hemorrhage, infection, or uncontrolled GVHD. Transfusions at higher platelet levels were maintained for patients receiving anticoagulant medications and patients with abnormal coagulation times, platelet dysfunction such as uremia, or other bleeding diatheses. Invasive procedures, anticoagulation management, prevention of a blood clot and management of central venous catheter-associated thrombosis required maintenance of higher platelet levels.
Infection surveillance, prophylaxis and pre-emptive therapy against cytomegalovirus
Cytomegalovirus (CMV) surveillance with polymerase chain reaction (PCR) or the pp65
antigenemia assay was performed on a weekly basis until day 100 as previously described.
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After day 100, surveillance and preemptive therapy were recommended for CMV intermediateand high-risk patients on a weekly or biweekly basis until day 365.
Ganciclovir preemptive treatment was started when CMV pp65 antigenemia/PCR became positive during the first 100 days after HCT. Ganciclovir (5 mg/kg IV twice daily) for 7 to 6 14 days was administered as induction therapy followed by a half-dose of ganciclovir (5 mg/kg IV daily) or valganciclovir 900 mg once a day orally as maintenance therapy until day 100. 20 All doses were adjusted based on the renal function according to manufacturers' recommendation.
After day 100, pre-emptive therapy was recommended for patients with CMV pp65 antigenemia or PCR >1000 copies/mL as previously described.
Pneumocystis jerovecii prophylaxis was performed with trimethoprim sulfamethoxazole as primary agent and dapsone as secondary agent. Identical doses of both drugs were used for all patients, regardless of conditioning regimen. 21 However, recipients of nonmyeloablative conditioning regimens started prophylaxis at day 28 after HCT while recipients of myeloablative transplantation received pretransplant dosing which was then resumed after neutrophil engraftment.
Definitions of cytopenias after day 28
We evaluated neutropenia, anemia and thrombocytopenia after day 28, and ganciclovir-related neutropenia. Ganciclovir-related neutropenia was defined as non-relapse-related neutropenia 
Statistical analysis
Characteristics of NM-HCT and M-HCT patients were summarized using frequency counts and percentages for categorical variables and medians and ranges for continuous variables. 
Results
Risk factors for cytopenias after day 28
Among the 1818 patients with neutrophil engraftment at day 28, 711 (39%) had at least one form of cytopenia after day 28: 103 (6%) had neutropenia only, 128 (7%) had anemia only, 102
(6%) had thrombocytopenia only and 123 (7%) had all three cytopenias. Neutropenia after day 28 was significantly more frequent in NM-HCT than in M-HCT (23% and 13%, respectively) ( Figure 1A ).
In univariate analysis, the risk factors for neutropenia (< 500/μL) after day 28 included patient age (> 40 years), recipient CMV seropositivity, patients at higher risk of CMV, unrelated donor status, receipt of NM-HCT, use of MMF, lower CD34+ cell dose (≤ 6.4×10 6 /kg) in the graft, chronic GVHD, high bilirubin level (> 6 mg/dl), and elevated creatinine (> 2 mg/dl) ( Table 2) . In a multivariate model, we identified patient age, CMV seropositivity, unrelated donor status, HLA mismatched donor, MMF use and lower CD34+ cell dose (≤ 6.4×10 6 /kg) as significant risk factors for neutropenia after day 28 in both HCT with bone marrow (BM) and peripheral blood stem cell (PBSC) ( Table 3 Results of univariate analyses for anemia and thrombocytopenia after day 28 are displayed in Table 4 . ABO-mismatched donor, patient age (> 40 years), female donor, patients at higher risk of CMV, unrelated donor, HLA-mismatched donor, BM as a stem cell source and lower CD34+ cell dose (≤ 6.4×10 6 /kg) were risk factors for anemia after day 28. Risk factors for thrombocytopenia after day 28 included ABO-mismatched donor, unrelated donor, HLAmismatched donor, BM as a stem cell source and CD34+ cell dose (≤ 6.4×10 6 /kg) ( Table 4) . In a multivariate model, ABO-mismatched donor, patient age (> 40 years), CMV infection, unrelated donor, HLA-mismatched donor and lower CD34+ cell dose (≤ 6.4×10 6 /kg) were identified as common risk factors for anemia and thrombocytopenia after day 28 in both HCT with BM and 9 PBSC (Table 5) . CMV serostatus was no longer significant when active posttransplant CMV infection was included in to the model. NM-HCT was significantly associated with a lower incidence of anemia and thrombocytopenia after day 28 in both univariate and multivariate models (Tables 4 and 5 ).
Risk factor for ganciclovir-related neutropenia
The cumulative incidence of GCV-N was similar for NM-HCT and M-HCT recipients (26% and 22%, respectively). A univariate model for GCV-N is shown in Table 2 . In the univariate model, we found patient age (> 40 years), unrelated donor status, MMF use, lower CD34+ cell dose (≤ 6.4×10 6 /kg) and high bilirubin level (> 6 mg/dl) to be significant risk factors for GCV-N ( Table 2 ).
All factors except MMF use and high bilirubin levels remained statistically significant risk factors for GCV-N ( Table 3) . Analysis of a lower threshold for neutropenia (< 200/μL) did not reveal additional risk factors (data not shown).
The impact of cytopenias after day 28 on non-relapse mortality
In a multivariate analysis of non-relapse mortality, we included acute GVHD, patient and donor age, patient and donor sex, patient CMV, donor relation, HLA disparity, stem cell source, MMF use and the intensity of the conditioning regimen as covariates. After adjustment for these factors, neutropenia, anemia and thrombocytopenia after day 28 were all significant independent risk factors for non-relapse mortality after HCT (neutropenia: HR=1.81, 95% CI Table 1 ).
Discussion
The study provides novel and somewhat unexpected results on the risk of cytopenias after HCT.
Older recipient age, low CD34+ cell dose, an unrelated donor, and HLA mismatch were risk factors for cytopenias after transplantation. Nonmyeloablative conditioning was associated with significantly reduced incidence of anemia and thrombocytopenia after day 28, but not neutropenia.
We hypothesized that nonmyeloablative conditioning is associated with less neutropenia after day 28. Surprisingly, this study could not find a significant reduction of neutropenia both overall and in the context of ganciclovir use. Overall, neutropenia after day 28 occurred in 13% of patients. The exact contribution of mycophenolate mofetil (MMF) to the relatively high rates of neutropenia in NM-HCT recipients cannot be determined since MMF was given to all patients receiving NM conditioning. MMF was significantly associated with neutropenia even after controlling for donor relatedness (which determined the duration of drug use). However, neutropenia is an important adverse effect of MMF and cumulative toxicity with ganciclovir is plausible and has been described. 22 Our study also identified other factors that might explain the high rate of neutropenia in NM-HCT. We found older recipient age to be a risk factor for both neutropenia after day 28 and ganciclovir-related neutropenia. NM-HCT is more commonly done in older patients. The effect of older recipient age may be mediated by subclinical renal dysfunction (especially tubular function 23 ), which may lead to inadvertent overdosing of myelotoxic drugs that are renally eliminated but only adjusted by creatinine clearance (which does not measure tubular function). Such effect would be consistent with the pharmacokinetic properties and the toxicity profile of ganciclovir, which includes predominantly neutropenia but not thrombocytopenia and anemia.
There are limited data on cytopenia after day 28 relative to the intensity of the conditioning regimen. Severe GVHD, myelotoxicity associated with drugs such as ganciclovir, previously reported unrelated donor, grade II-IV acute GVHD, impaired renal function, the combination of busulfan and cyclophosphamide, TBI, stem cell dose and infections as risk factors for secondary failure of platelet recovery among M-HCT. 5 The present study extended our previous findings that NM-HCT may also have protective effects against thrombocytopenia and anemia. 24 We identified HLA mismatch, CMV serostatus and the CD34+ cell count as additional risk factors for both outcomes in multivariable models. We speculate that the higher doses of CD34+ cells and the reduced intensity of the conditioning regimen used in NM-HCT contributed to the lower rates of anemia and thrombocytopenia.
The CD34+ cell dose rather than the stem cell source per se was an important risk factor for all cytopenias examined in this study. When the cell dose was included in the multivariable models the stem cell source was no longer significant, suggesting that the protective effect of peripheral blood stem cells for anemia and thrombocytopenia seen in the univariate analyses was mediated by the higher number dose of CD34+ cells (Tables 3 and 5 ).
CMV serostatus of the recipient was a risk factor for both anemia and thrombocytopenia requiring blood products (Table 5) , a finding not previously appreciated in HCT recipients.
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When CMV serostatus and active CMV infection were included in a multivariable analysis, active CMV infection remained significant while CMV serostatus was no longer significant, suggesting that active CMV infection or preemptive therapy was responsible for the effect. The relative contribution of CMV infection versus its treatment cannot be determined from this study.
Ganciclovir has not been associated with thrombocytopenia or anemia or an increased use of blood products in several placebo-controlled randomized trials in HCT recipients. 6, 26, 27 A previous risk factor analysis in myeloablative HCT recipients between 1990 and 1997 did not identify CMV serostatus as a risk factor for thrombocytopenia, but the use of platelet products was not analyzed in that study. 5 Based on the lack of association with anemia and 12 thrombocytopenia in randomized trials of ganciclovir, we speculate that CMV infection itself might be responsible for the effect. 4, 28 Our study has several imitations, including the retrospective nature of the analysis and that the analysis of concomitant medications was performed by protocol only. With regard to the nonmyeloablative conditioning, the results can probably not be extrapolated to other types of reduced-intensity conditioning regimens. However, the strength of the analyses lies in its large sample size, the number of clinically important factors analyzed, a homogeneous transplant protocol, and highly standardized supportive care strategies.
In conclusion, the study provides a comprehensive analysis of factors associated with cytopenias 28 days after HCT. Unexpectedly, NM-HCT did not reduce the risk of neutropenia after day 28 overall or in the context of ganciclovir. The high rates of neutropenia appear to be linked to the use of MMF and ganciclovir, emphasizing the need for less toxic immunosuppressive and anti-CMV drugs or strategies. In contrast, NM-HCT showed a protective effect against anemia and thrombocytopenia after day 28, probably through less toxic conditioning and higher dose of CD34+ stem cells or use of PBSC almost exclusively. Finally, the study identified potentially modifiable factors that could be used before transplantation to minimize the risk of post-transplant cytopenias, including the use of nonmyeloablative conditioning, optimized HLA matching, and higher doses of CD34+ cell infusions.
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